Publications
2024
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
Leong, I. U. S., Cabrera, C. P., Cipriani, V., Ross, P. J., Turner, R. M., Stuckey, A., . . . McDonagh, E. M. (2024). Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2302761. doi:10.1200/jco.23.02761
Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross, B., Turner, R. M., Zhang, J. E., & Pirmohamed, M. (2024). Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?. The pharmacogenomics journal, 24(2), 7. doi:10.1038/s41397-024-00329-y
Chapter 40 Pharmacogenomics in cardiovascular disease
Turner, R. M., & Pirmohamed, M. (2024). Chapter 40 Pharmacogenomics in cardiovascular disease. In Diagnostic Molecular Pathology (pp. 623-642). Elsevier. doi:10.1016/b978-0-12-822824-1.00001-8
2023
A Survey of the UK Pharmacy Profession's Educational Needs on Pharmacogenomics
Rollinson, V., French, N., Turner, R., & Pirmohamed, M. (2023). A Survey of the UK Pharmacy Profession's Educational Needs on Pharmacogenomics. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2023. doi:10.1155/2023/2388845
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., . . . Ubiquitous Pharmacogenomics Consortium. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.. Lancet (London, England), 401(10374), 347-356. doi:10.1016/s0140-6736(22)01841-4
Pharmacogenomics in cardiovascular disease
Turner, R. M., & Pirmohamed, M. (2024). Pharmacogenomics in cardiovascular disease. In Diagnostic Molecular Pathology (pp. 623-642). Elsevier. doi:10.1016/b978-0-12-822824-1.00001-8
2022
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (vol 8, pg 85, 2022)
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., . . . Caulfield, M. J. (2022). The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy (vol 8, pg 85, 2022). EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 9(1), 116. doi:10.1093/ehjcvp/pvac038
Polygenic risk scores: An overview from bench to bedside for personalised medicine
Cross, B., Turner, R., & Pirmohamed, M. (2022). Polygenic risk scores: An overview from bench to bedside for personalised medicine. FRONTIERS IN GENETICS, 13. doi:10.3389/fgene.2022.1000667
Pharmacogenomics: Relevance and opportunities for clinical pharmacology
Turner, R. M., Magavern, E. F., & Pirmohamed, M. (2022). Pharmacogenomics: Relevance and opportunities for clinical pharmacology. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(9), 3943-3946. doi:10.1111/bcp.15329
Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials
Asiimwe, I. G., Pushpakom, S. P., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2022). Cardiovascular drugs and COVID-19 clinical outcomes: a systematic review and meta-analysis of randomized controlled trials. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 88(8), 3577-3599. doi:10.1111/bcp.15331
Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries.
Blagec, K., Swen, J. J., Koopmann, R., Cheung, K. -C., Crommentuijn-van Rhenen, M., Holsappel, I., . . . Ubiquitous Pharmacogenomics Consortium. (2022). Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries.. PloS one, 17(6), e0268534. doi:10.1371/journal.pone.0268534
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms
Cooper-DeHoff, R. M., Niemi, M., Ramsey, L. B., Luzum, J. A., Tarkiainen, E. K., Straka, R. J., . . . Voora, D. (2022). The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(5), 1007-1021. doi:10.1002/cpt.2557
A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring
Green, T. J., Walker, L. E., & Turner, R. M. (2022). A European cross-sectional survey to investigate how involved doctors training in clinical pharmacology are in drug concentration monitoring. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. doi:10.1007/s00228-022-03316-z
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., . . . Caulfield, M. J. (2022). Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 8(1), 100-103. doi:10.1093/ehjcvp/pvab063
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., . . . Caulfield, M. J. (2022). The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 8(1), 85-99. doi:10.1093/ehjcvp/pvab018
Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol
Fontana, V., Turner, R. M., Francis, B., Yin, P., Puetz, B., Hiltunen, T. P., . . . Pirmohamed, M. (2022). Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 15, 249-260. doi:10.2147/PGPM.S352719
Pharmacogenomics of Anti-Cancer Drugs
Carr, D. F., Turner, R. M., & Pirmohamed, M. (2022). Pharmacogenomics of Anti-Cancer Drugs. In Comprehensive Pharmacology (pp. 311-325). Elsevier. doi:10.1016/b978-0-12-820472-6.00159-6
2021
Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis
Asiimwe, I. G., Pushpakom, S., Turner, R. M., Kolamunnage-Dona, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(12), 4534-+. doi:10.1111/bcp.14927
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
Magavern, E. F., Kaski, J. C., Turner, R. M., Janmohamed, A., Borry, P., & Pirmohamed, M. (2021). The Interface of Therapeutics and Genomics in Cardiovascular Medicine. CARDIOVASCULAR DRUGS AND THERAPY, 35(3), 663-676. doi:10.1007/s10557-021-07149-3
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
Carr, D. F., Turner, R. M., & Pirmohamed, M. (2021). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(2), 237-255. doi:10.1111/bcp.14407
2020
Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study
Turner, R. M., de Koning, E. M., Fontana, V., Thompson, A., & Pirmohamed, M. (2020). Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. BMC MEDICINE, 18(1). doi:10.1186/s12916-020-01827-z
Pharmacogenomics for Primary Care: An Overview
Rollinson, V., Turner, R., & Pirmohamed, M. (2020). Pharmacogenomics for Primary Care: An Overview. GENES, 11(11). doi:10.3390/genes11111337
Pharmacogenomics in the UK National Health Service: opportunities and challenges
Turner, R. M., Newman, W. G., Bramon, E., McNamee, C. J., Wong, W. L., Misbah, S., . . . Pirmohamed, M. (2020). Pharmacogenomics in the UK National Health Service: opportunities and challenges. Pharmacogenomics, 21(17), 1237-1246. doi:10.2217/pgs-2020-0091
A Review of the Important Role of <i>CYP2D6</i> in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020). A Review of the Important Role of <i>CYP2D6</i> in Pharmacogenomics. GENES, 11(11). doi:10.3390/genes11111295
A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites
Turner, R. M., Fontana, V., Zhang, J. E., Carr, D., Yin, P., FitzGerald, R., . . . Pirmohamed, M. (2020). A Genome‐wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites. Clinical Pharmacology and Therapeutics, 108(2), 287-297. doi:10.1002/cpt.1820
Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
van der Wouden, C. H., Bohringer, S., Cecchin, E., Cheung, K. -C., Lucia Davila-Fajardo, C., Deneer, V. H. M., . . . Consor, U. P. (2020). Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenetics and Genomics, 30(6), 131-144. doi:10.1097/FPC.0000000000000405
Pharmacogenetics and statin-related myopathy: what do we know?
Turner, R. M., Radman, I., Bozina, N., & Alfirevic, A. (2020). Pharmacogenetics and statin-related myopathy: what do we know?. PHARMACOGENOMICS, 21(12), 821-825. doi:10.2217/pgs-2020-0041
Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response
Carr, D., Turner, R. M., & Pirmohamed, M. (n.d.). Pharmacogenomics of anticancer drugs: Personalising the choice and dose to manage drug response. British Journal of Clinical Pharmacology. doi:10.1111/bcp.14407
Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention
Turner, R. M., Fontana, V., FitzGerald, R., Morris, A. P., & Pirmohamed, M. (2020). Investigating the clinical factors and comedications associated with circulating levels of atorvastatin and its major metabolites in secondary prevention. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 86(1), 62-74. doi:10.1111/bcp.14133
2019
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components
Turner, R. M., & Pirmohamed, M. (2020). Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. JOURNAL OF CLINICAL MEDICINE, 9(1). doi:10.3390/jcm9010022
Pharmacogene variation in the UK 100,000 Genomes Project: an analysis of 60,221 individuals
Turner, R. M., Genomics England Research Consortium., & Pirmohamed, M. (2019). Pharmacogene variation in the UK 100,000 Genomes Project: an analysis of 60,221 individuals. Poster session presented at the meeting of Genomics England Research Conference. London, UK.
Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts
Just, K. S., Turner, R. M., Dolzan, V., Cecchin, E., Swen, J. J., Gurwitz, D., & Stingl, J. C. (2019). Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. CLINICAL PHARMACOLOGY & THERAPEUTICS, 106(2), 313-316. doi:10.1002/cpt.1471
2018
Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort
Turner, R. M., Fontana, V., Bayliss, M., Whalley, S., Castelazo, A. S., & Pirmohamed, M. (2018). Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 159, 272-281. doi:10.1016/j.jpba.2018.06.062
Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery
Turner, R. M., & Pirmohamed, S. M. (2018). Pharmacogenetics and Pharmacogenomics in Cardiovascular Medicine and Surgery. In Cardiovascular Genetics and Genomics (pp. 119-172). Springer International Publishing. doi:10.1007/978-3-319-66114-8_5
2017
Pharmacogenomics: an overview
Pharmacogenomics: an overview (2017). Clinical Pharmacist. doi:10.1211/cp.2017.20203640
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (vol 101, pg 341, 2017)
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Davila-Fajardo, C. L., Deneer, V. H., . . . Guchelaar, H. -J. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (vol 101, pg 341, 2017). CLINICAL PHARMACOLOGY & THERAPEUTICS, 102(1), 152. doi:10.1002/cpt.725
Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Davila-Fajardo, C. L., Deneer, V. H., . . . Guchelaar, H. -J. (2017). Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. CLINICAL PHARMACOLOGY & THERAPEUTICS, 101(3), 341-358. doi:10.1002/cpt.602
The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites
Turner, R. M., Bayliss, M., Carr, D., Kitteringham, N., Henderson, C., & Pirmohamed, M. (2016, December 13). The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites. In http://www.pa2online.org/abstract/abstract.jsp?abid=33238&kw=P450%20oxidoreductase&cat=-1&period=-1. London, UK.
Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome
Turner, R. M., Yin, P., Hanson, A., FitzGerald, R., Morris, A. P., Stables, R. H., . . . Pirmohamed, M. (2017). Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome. Journal of Clinical Lipidology, 11(1), 204-214. doi:10.1016/j.jacl.2016.12.007
Statin-associated muscle toxicity : clinical and genomic perspectives
Turner, R. (2017). Statin-associated muscle toxicity : clinical and genomic perspectives.
2016
SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2016). SNP-Treatment Interactions of Cardiovascular Medications and Risk of Acute Coronary Syndrome Recurrence. In GENETIC EPIDEMIOLOGY Vol. 40 (pp. 672). Retrieved from https://www.webofscience.com/
Personalized Medicine in Cardiovascular Disease
Turner, R. M., Bula, M., & Pirmohamed, M. (2017). Personalized Medicine in Cardiovascular Disease. In DIAGNOSTIC MOLECULAR PATHOLOGY: A GUIDE TO APPLIED MOLECULAR TESTING (pp. 457-471). doi:10.1016/B978-0-12-800886-7.00036-4
2015
Parsing interindividual drug variability: an emerging role for systems pharmacology
Turner, R. M., Park, B. K., & Pirmohamed, M. (2015). Parsing interindividual drug variability: an emerging role for systems pharmacology. WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 7(4), 221-241. doi:10.1002/wsbm.1302
Pharmacogenetics of Adverse Drug Reactions
Turner, R. M., & Pirmohamed, M. (2015). Pharmacogenetics of Adverse Drug Reactions. In PREVENTIVE AND PREDICTIVE GENETICS: TOWARDS PERSONALISED MEDICINE (Vol. 9, pp. 109-156). doi:10.1007/978-3-319-15344-5_6
The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study
Yin, P., Jorgensen, A., Morris, A., Turner, R., Fitzgerald, R., Stables, R., . . . Pirmohamed, M. (2015). The Influence of Pharmacogenetics on the Time to Acute Coronary Syndrome Recurrence in a UK Cohort Study. In HUMAN HEREDITY Vol. 80 (pp. 123). Retrieved from https://www.webofscience.com/
2014
Cardiovascular Pharmacogenomics: Expectations and Practical Benefits
Turner, R. M., & Pirmohamed, M. (2014). Cardiovascular Pharmacogenomics: Expectations and Practical Benefits. CLINICAL PHARMACOLOGY & THERAPEUTICS, 95(3), 281-293. doi:10.1038/clpt.2013.234
Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis
Turner, R. M., Kwok, C. S., Chen-Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2014). Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78(2), 258-273. doi:10.1111/bcp.12306
2013
Dose and duration relationship between pioglitazone and associated risk of bladder cancer: a systematic review and meta-analysis
Singh, S., Loke, Y., Kwok, C. S., Chen-Turner, C., Turner, R. M., & Maduakor, C. A. (2013). Dose and duration relationship between pioglitazone and associated risk of bladder cancer: a systematic review and meta-analysis. In Journal of General Internal Medicine Vol. 28 (pp. S66). Denver, US: Springer Nature.
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.
Jennings, B. A., Loke, Y. K., Skinner, J., Keane, M., Chu, G. S., Turner, R., . . . Willis, G. (2013). Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines.. PloS one, 8(10), e78053. doi:10.1371/journal.pone.0078053
2012
Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies.
Kwok, C. S., Yeong, J. K. -Y., Turner, R. M., Cavallazzi, R., Singh, S., & Loke, Y. K. (2012). Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies.. European journal of clinical pharmacology, 68(5), 747-755. doi:10.1007/s00228-011-1159-4
2011
A new anaesthetic receptacle.
Turner, R. (2011). A new anaesthetic receptacle.. Anaesthesia, 66(5), 401-402. doi:10.1111/j.1365-2044.2011.06745.x